Jefferies Group Reaffirms Buy Rating for TherapeuticsMD Inc (TXMD)
A number of other equities research analysts have also weighed in on TXMD. Oppenheimer Holdings, Inc. initiated coverage on TherapeuticsMD in a research report on Tuesday, November 22nd. They set an outperform rating and a $12.00 price objective on the stock. Zacks Investment Research upgraded TherapeuticsMD from a sell rating to a hold rating in a research report on Thursday, November 24th. Guggenheim restated a buy rating on shares of TherapeuticsMD in a research report on Tuesday, November 29th. Goldman Sachs Group, Inc. (The) restated a buy rating and set a $10.50 price objective on shares of TherapeuticsMD in a research report on Sunday, December 4th. Finally, Stifel Nicolaus boosted their price objective on TherapeuticsMD from $14.00 to $17.00 and gave the stock a buy rating in a research report on Tuesday, December 6th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $14.38.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 5.82 on Friday. TherapeuticsMD has a 52-week low of $4.39 and a 52-week high of $9.29. The stock’s 50 day moving average price is $6.04 and its 200-day moving average price is $6.75. The company’s market capitalization is $1.14 billion.
TRADEMARK VIOLATION NOTICE: “Jefferies Group Reaffirms Buy Rating for TherapeuticsMD Inc (TXMD)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be viewed at http://www.watchlistnews.com/jefferies-group-reaffirms-buy-rating-for-therapeuticsmd-inc-txmd/1061473.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of TherapeuticsMD by 7.1% in the third quarter. BlackRock Inc. now owns 16,303 shares of the company’s stock valued at $111,000 after buying an additional 1,080 shares during the last quarter. Traynor Capital Management Inc. increased its position in shares of TherapeuticsMD by 21.2% in the third quarter. Traynor Capital Management Inc. now owns 20,000 shares of the company’s stock valued at $119,000 after buying an additional 3,500 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of TherapeuticsMD during the third quarter valued at approximately $137,000. Principal Financial Group Inc. increased its position in shares of TherapeuticsMD by 1.3% in the third quarter. Principal Financial Group Inc. now owns 20,333 shares of the company’s stock valued at $138,000 after buying an additional 261 shares during the last quarter. Finally, DIAM Co. Ltd. bought a new position in shares of TherapeuticsMD during the third quarter valued at approximately $139,000.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.